TL;DR: A BPC-157 calculator converts vial size and solvent volume into exact per-injection volumes. For a 10 mg vial with 3 mL bacteriostatic water, each 0.1 mL (100 Β΅L) draw equals 333 mcg. Commonly referenced research protocols range from 250–500 mcg daily, administered subcutaneously or intraperitoneally in animal models.

If you've ever stared at a lyophilized BPC-157 vial wondering how many units to draw on an insulin syringe, you're not alone β€” this is where most reconstitution mistakes happen. A BPC-157 calculator eliminates the guesswork by converting your vial concentration into precise injection volumes, so every data point in a research protocol is reproducible. This guide walks through the full calculation method, standard reconstitution steps, commonly referenced dosing protocols from preclinical literature, stacking considerations, and storage requirements. For a ready-to-use tool, visit our peptide reconstitution calculator.

Research Use Only: BPC-157 and all peptides referenced in this article are intended solely for laboratory research purposes. They are not approved for human consumption, and nothing in this guide constitutes medical advice or a treatment recommendation.

What Is BPC-157 and Why Does Dosing Math Matter?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a naturally occurring protein in human gastric juice. Its preclinical profile is unusually broad: published rodent studies document accelerated tendon-to-bone healing, gastric mucosal cytoprotection, peripheral nerve regeneration, and angiogenic activity mediated largely through upregulation of vascular endothelial growth factor (VEGF) and modulation of the nitric oxide synthase (NOS) pathway.

Because BPC-157 is supplied as a lyophilized (freeze-dried) powder, researchers must reconstitute it before use. The concentration produced during reconstitution directly determines how many microliters must be drawn per dose β€” and a 2Γ— error in that calculation means every subsequent injection in a study delivers half or double the intended amount. That's why a reliable BPC-157 calculator is a foundational tool, not a convenience.

BPC-157: 15-Amino-Acid Sequence Overview Gly Glu Pro Pro Pro Gly Lys Pro Ala Asp Gly His Trp His Ser Standard residues Glycine residues Alanine Aromatic/polar residues 15-mer sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Gly-His-Trp-His-Ser

How the BPC-157 Calculator Works: The Core Math

The calculation is straightforward once you understand the three variables involved:

  • Peptide mass (mg or mcg) β€” the amount of BPC-157 in the vial (commonly 5 mg or 10 mg)
  • Reconstitution volume (mL) β€” the volume of bacteriostatic water added
  • Target dose (mcg) β€” the amount specified in the research protocol

The formula:

Concentration (mcg/mL) = [Vial mass (mcg)] Γ· [Solvent added (mL)]

Injection volume (mL) = [Target dose (mcg)] Γ· [Concentration (mcg/mL)]

Syringe units (IU) = Injection volume (mL) Γ— 100
(for standard 100-unit insulin syringes)

Worked Example: 10 mg Vial + 3 mL Bacteriostatic Water

  • 10 mg = 10,000 mcg peptide mass
  • Concentration: 10,000 Γ· 3.0 = 3,333 mcg/mL
  • For a 250 mcg dose: 250 Γ· 3,333 = 0.075 mL β†’ 7.5 IU
  • For a 500 mcg dose: 500 Γ· 3,333 = 0.15 mL β†’ 15 IU

Our peptide calculator handles this automatically β€” enter your vial size, solvent volume, and target dose, and it returns the exact syringe draw with unit markings.

BPC-157 Calculator: Step-by-Step Flowchart STEP 1 Enter vial size (e.g., 10 mg) STEP 2 Enter solvent vol. (e.g., 3.0 mL BAC water) STEP 3 Enter target dose (e.g., 250 mcg) RESULT Draw volume β†’ 7.5 IU / 0.075 mL Quick Reference: 10 mg vial concentrations by solvent volume Solvent Added Concentration 250 mcg draw 500 mcg draw 2.0 mL 5,000 mcg/mL 5 IU (0.05 mL) 10 IU (0.10 mL) 3.0 mL 3,333 mcg/mL 7.5 IU (0.075 mL) 15 IU (0.15 mL) 5.0 mL 2,000 mcg/mL 12.5 IU (0.125 mL) 25 IU (0.25 mL) Green row = most common research protocol reconstitution ratio. Use our calculator for other vial sizes.

Step-by-Step Reconstitution Protocol

Accurate reconstitution preserves peptide integrity and ensures the concentration your BPC-157 calculator outputs actually matches what's in the syringe.

  1. Prepare aseptic workspace. Clean the work surface; use 70% isopropyl alcohol to swab both the vial septum and the bacteriostatic water vial cap. Allow to dry for 30 seconds.
  2. Draw bacteriostatic water. Using a sterile syringe, draw the intended volume (commonly 2–3 mL for a 10 mg vial).
  3. Inject slowly against the vial wall. Insert the needle into the BPC-157 vial and direct the stream along the inner glass surface β€” not directly onto the lyophilized cake. This prevents foaming and peptide denaturation from mechanical shear.
  4. Dissolve gently. Swirl or roll the vial slowly between your palms. Do not vortex or shake. The powder should fully dissolve into a clear solution within 60–90 seconds.
  5. Label and date. Mark the vial with the reconstitution date and your calculated concentration (mcg/mL).
  6. Refrigerate at 2–8Β°C (36–46Β°F). Protect from light. Reconstituted BPC-157 in bacteriostatic water is stable for approximately 4–6 weeks under these conditions.

If you're also working with other peptides requiring reconstitution, our peptide dosing calculator supports multiple compound entries in a single session.

Using the BPC-157 Calculator for Different Research Protocols

Preclinical literature describes several distinct dosing paradigms depending on the injury model and administration route. The table below summarizes commonly referenced protocols and their calculator inputs.

Protocol Dose Frequency Duration IU Draw (3 mL/10 mg vial)
Standard recovery 250 mcg Once daily 4–8 weeks 7.5 IU
Accelerated recovery 250 mcg Γ— 2 Twice daily 4–6 weeks 7.5 IU Γ— 2
High-dose soft tissue 500 mcg Once daily 4–6 weeks 15 IU
GI mucosal model 500 mcg Once daily 4–8 weeks 15 IU
Localized injury 250 mcg 1–2Γ— daily (local SQ) 4–8 weeks 7.5 IU

All values above assume a 10 mg vial reconstituted in 3.0 mL bacteriostatic water (3,333 mcg/mL). If your reconstitution volume differs, recalculate via the calculator β€” even a 0.5 mL discrepancy shifts the draw by ~10%.

Mechanism of Action: Why BPC-157 Dosing Precision Matters

BPC-157 operates through at least three overlapping pathways that are dose-sensitive in rodent models:

  • VEGF upregulation and angiogenesis: BPC-157 increases VEGF expression, which drives new capillary formation at injury sites. This pathway shows a dose-response relationship in transected tendon models (Sikiric et al., 2018).
  • Nitric oxide modulation: The peptide interacts with the NOS pathway to promote vasodilation and reduce ischemic damage. Lower doses (1–2 mcg/kg in rodent studies) have been sufficient to elicit NO-dependent effects, suggesting high potency relative to molecular weight.
  • Growth hormone receptor sensitization: BPC-157 upregulates GH receptor expression in injured tissue, which may explain synergistic effects when co-administered with growth hormone secretagogues like Ipamorelin. This mechanism makes dose stacking calculations particularly important when combining peptides.

BPC-157 Stacks: Calculator Considerations for Multi-Peptide Protocols

BPC-157 is commonly paired with other peptides in preclinical tissue-repair research:

BPC-157 + TB-500

TB-500 (Thymosin Beta-4) promotes actin polymerization and cell migration, while BPC-157 drives angiogenesis. The two mechanisms are complementary rather than redundant. When stacking, each peptide requires its own reconstitution calculation β€” they are typically supplied in separate vials and drawn independently. Use our calculator for each compound entry. Standard preclinical stack references cite BPC-157 at 250 mcg and TB-500 at 750 mcg–2 mg in rodent models.

BPC-157 + Growth Hormone Secretagogues

Some researchers combine BPC-157 with GHRP-6 or Ipamorelin to leverage GH receptor upregulation. This requires separate reconstitution math for each peptide since GHRP-6 is often supplied in 5 mg vials and dosed at 100–300 mcg per administration in animal studies β€” a very different concentration profile than BPC-157.

Safety Profile and Preclinical Observations

BPC-157 is notable for a favorable tolerability profile in preclinical models. Rodent studies have administered it over extended durations without observed organ toxicity. That said, researchers should be aware of several considerations:

  • Injection site reactions: Mild transient erythema (redness) at the subcutaneous injection site is the most commonly reported finding, typically resolving within a few hours.
  • Nausea observations: Occasional GI disturbance noted in some models, potentially mitigated by timing administration with feeding.
  • Angiogenic caution: Due to VEGF pathway activation, researchers studying tumor biology should note that pro-angiogenic activity could theoretically support tumor vascularization. This is a relevant consideration in any oncology-adjacent research design.
  • No human clinical trials to date: All safety data is from in vitro and in vivo animal models. No phase I/II/III human safety data has been published as of 2026.

Storage After Reconstitution

Peptide stability is concentration- and temperature-dependent. For reconstituted BPC-157:

  • Refrigerated (2–8Β°C): Stable approximately 4–6 weeks in bacteriostatic water
  • Frozen (βˆ’20Β°C): Lyophilized (unreconstituted) powder stable for 12–24 months; avoid repeated freeze-thaw cycles post-reconstitution
  • Light exposure: UV degrades peptide bonds β€” store in opaque or amber vials, or wrapped in foil
  • Bacteriostatic water vs. sterile water: Bacteriostatic water (0.9% benzyl alcohol) is strongly preferred for multi-draw vials due to its antimicrobial properties; sterile water should be used within 24 hours of reconstitution
BPC-157 Storage Stability Timeline 0 6 wks 12 mos 24 mos 36 mos Lyophilized powder at βˆ’20Β°C (12–24 months) Reconstituted in BAC water at 2–8Β°C (4–6 weeks) Reconstituted in sterile water at 2–8Β°C (~24 hours) Avoid freeze-thaw cycles post-reconstitution. Protect all forms from UV light exposure.

BPC-157 vs. Comparable Research Peptides

Researchers frequently compare BPC-157 to two other tissue-repair peptides:

  • BPC-157 vs. TB-500: BPC-157 shows stronger GI and tendon healing data; TB-500 has more robust muscle and connective tissue data in large-animal models. Their mechanisms are complementary, which is why the stack is common in preclinical protocols.
  • BPC-157 vs. GHK-Cu: GHK-Cu (copper peptide) operates primarily via collagen synthesis and skin/hair follicle regeneration pathways. BPC-157 penetrates deeper tissue models (muscle, tendon, nerve, GI mucosa) more consistently in published literature. They target different tissue compartments and are rarely stacked.

Common BPC-157 Calculator Errors to Avoid

  1. Confusing mg and mcg: 10 mg = 10,000 mcg. If you enter "10" as your mass and target "250 mcg" without unit conversion, the output will be off by 1,000Γ—.
  2. Ignoring dead volume: Insulin syringes have 5–8 Β΅L of dead space in the needle hub. For very small draws (under 10 IU), this can represent a meaningful percentage error.
  3. Rounding solvent volume: If you intended to add 2.0 mL but the plunger stopped at 1.85 mL, your actual concentration is 5,405 mcg/mL β€” not 5,000. Always measure reconstitution volume precisely and re-enter the actual number into the calculator.
  4. Using the wrong vial mass: Some suppliers label vials as "5 mg peptide" but include excipients that add mass. Confirm peptide purity (β‰₯98% by HPLC) and net peptide content before calculating.

Frequently Asked Questions

How does a BPC-157 calculator convert mcg to syringe units?

It divides your target dose (in mcg) by the reconstituted concentration (mcg/mL) to get the injection volume in mL, then multiplies by 100 to convert to IU on a standard insulin syringe. For a 250 mcg dose from a 10 mg vial in 3 mL BAC water (3,333 mcg/mL), the draw is 0.075 mL = 7.5 IU.

How much bacteriostatic water should I add to a 10 mg BPC-157 vial?

Most preclinical protocols use 2–3 mL, with 3 mL being the most common choice as it yields a 3,333 mcg/mL concentration and produces conveniently measurable draw volumes on a 100-unit insulin syringe. Adding more solvent lowers concentration and increases draw volumes, which can be useful for very small doses.

What is the most commonly referenced BPC-157 research dose?

Published rodent studies most frequently use 10 mcg/kg intraperitoneally. Translated to commonly referenced human-equivalent reference protocols (not for human use), 250 mcg once or twice daily is the most frequently cited range in preclinical extrapolation literature. These are research reference points only.

How long is reconstituted BPC-157 stable?

In bacteriostatic water stored at 2–8Β°C and protected from light, reconstituted BPC-157 is generally considered stable for 4–6 weeks. Lyophilized powder stored at βˆ’20Β°C retains integrity for 12–24 months when not exposed to repeated temperature fluctuations.

Can BPC-157 be combined with TB-500 in the same syringe?

While some researchers combine them in a single draw to reduce injection frequency, the two peptides should be reconstituted separately and drawn into the same syringe immediately before use β€” not pre-mixed in a shared vial β€” to avoid stability interference. Calculate each peptide's volume independently using the peptide calculator.

References

  1. Sikiric, P., Seiwerth, S., Rucman, R., et al. (2018). "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Current Pharmaceutical Design, 24(18), 1990–2001. Demonstrated cytoprotective and angiogenic effects in GI and tendon models. View source
  2. Chang, C.H., Tsai, W.C., Lin, M.S., et al. (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology, 110(3), 774–780. Found accelerated tendon-to-bone healing and improved biomechanical properties. View source
  3. Pevec, D., Novinscak, T., Brcic, L., et al. (2010). "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Medical Science Monitor, 16(3), BR81–88. Showed preserved muscle healing under corticosteroid-induced impairment conditions.
  4. Sikiric, P., Hahm, K.B., Blagaic, A.B., et al. (2020). "Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response." Biomedicines, 8(10), 405. Comprehensive review of BPC-157's systemic effects including neuroprotection and nitric oxide modulation. View source
  5. Thepeptidereport.com. (2024). "BPC-157 Peptide Dosage Protocol." Detailed reconstitution steps and protocol reference ranges for research use. View source